Log In
Print
BCIQ
Print
Print this Print this
 

DAC HYP, Daclizumab high-yield process

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionHumanized mAb against IL-2 receptor alpha chain (CD25)
Molecular Target Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of ActionBinds interleukin-2 (IL-2) receptor alpha chain (CD25); Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat relapsing-remitting multiple sclerosis (RRMS)
Regulatory Designation

Partner

Biogen Idec Inc.; UCB Group; UCB Group


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today